» Authors » Nathan Herrmann

Nathan Herrmann

Explore the profile of Nathan Herrmann including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 439
Citations 11210
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
21.
Anderson J, Rashidi-Ranjbar N, Nazeri A, Chad J, Zhukovsky P, Mulsant B, et al.
Biol Psychiatry Glob Open Sci . 2024 Feb; 4(1):374-384. PMID: 38298786
Background: Major depressive disorder (MDD) in late life is a risk factor for mild cognitive impairment (MCI) and Alzheimer's disease. However, studies of gray matter changes have produced varied estimates...
22.
Song B, Azhar L, Koo G, Marzolini S, Gallagher D, Swardfager W, et al.
Neurobiol Aging . 2023 Dec; 135:15-25. PMID: 38147807
Impaired angiogenesis is associated with cognitive decline in older adults. While exercise has been broadly associated with increased angiogenesis, the relevant mechanisms in older adults are not clear. Here, we...
23.
Soffer M, Butters M, Herrmann N, Black S, Kumar S, Pugh B, et al.
J Int Neuropsychol Soc . 2023 Dec; 30(5):471-478. PMID: 38088261
Objective: Previous findings suggest that time setting errors (TSEs) in the Clock Drawing Test (CDT) may be related mainly to impairments in semantic and executive function. Recent attempts to dissociate...
24.
Wu C, Wang C, Saskin R, Shah B, Kapral M, Lanctot K, et al.
J Intern Med . 2023 Sep; 295(1):68-78. PMID: 37747779
Background: Metformin has been suggested to reduce dementia risk; however, most epidemiologic studies have been limited by immortal time bias or confounding due to disease severity. Objectives: To investigate the...
25.
Gaur A, Rivet L, Mah E, Bawa K, Gallagher D, Herrmann N, et al.
Ageing Res Rev . 2023 Aug; 91:102046. PMID: 37647995
Mild cognitive impairment (MCI) is a well-established prodromal stage of dementia (e.g., Alzheimer's disease) that is often accompanied by early signs of neurodegeneration. To facilitate a better characterization of the...
26.
Azami H, Zrenner C, Brooks H, Zomorrodi R, Blumberger D, Fischer C, et al.
Alzheimers Res Ther . 2023 Aug; 15(1):133. PMID: 37550778
Background: Alzheimer's dementia (AD) is associated with electroencephalography (EEG) abnormalities including in the power ratio of beta to theta frequencies. EEG studies in mild cognitive impairment (MCI) have been less...
27.
Clark E, Perin J, Herrmann N, Brawman-Mintzer O, Lanctot K, Lerner A, et al.
Alzheimers Dement (N Y) . 2023 Aug; 9(3):e12403. PMID: 37538343
Introduction: Methylphenidate has been shown to improve apathy in patients with Alzheimer's disease (AD). The authors evaluated the impact of methylphenidate on neuropsychiatric symptoms (NPS) of AD, excluding apathy, using...
28.
Lanctot K, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, et al.
Am J Geriatr Psychiatry . 2023 Jun; 31(12):1077-1087. PMID: 37385898
Objective: The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) found that methylphenidate was effective in treating apathy with a small-to-medium effect size but showed heterogeneity in response. We assessed...
29.
Marawi T, Zhukovsky P, Rashidi-Ranjbar N, Bowie C, Brooks H, Fischer C, et al.
Biol Psychiatry . 2023 Jun; 94(12):913-923. PMID: 37271418
Background: Almost half of older patients with major depressive disorder (MDD) present with cognitive impairment, and one-third meet diagnostic criteria for mild cognitive impairment (MCI). However, mechanisms linking MDD and...
30.
Anita N, Kwan F, Ryoo S, Major-Orfao C, Lin W, Noor S, et al.
J Lipid Res . 2023 May; 64(7):100395. PMID: 37245563
Type 2 diabetes mellitus (T2DM) increases the risk of cognitive decline and dementia. Disruptions in the cytochrome P450-soluble epoxide hydrolase (CYP450-sEH) pathway have been reported in T2DM, obesity and cognitive...